Le Lézard
Classified in: Health
Subject: ACC

Change in the Number of Shares and Votes in Q-linea AB


STOCKHOLM, July 31, 2019 /PRNewswire/ -- Q-linea AB (publ) ("Q-linea" or "the Company"), today announced that the number of shares and votes in Q-linea has increased during the month of July due to the new share issue carried out to ensure delivery of performance shares within the framework of the long-term incentive programme that was resolved by the annual general meeting on 22 May 2019. A total of 117,424 shares and votes have been added.

At 31 July 2019, which is the last trading day in July, the number of shares and votes in the Company amounts to 23,235,387. All shares are ordinary shares.

This information is information that Q-linea AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication on 31 July 2019 at 08.30 AM CET.

About Q-linea

Q-linea is an innovative research, development and manufacturing company that primarily develops instruments and disposables for rapid and reliable infection diagnostics. Q-linea's vision is to help save lives by ensuring antibiotics continue to be an effective treatment for future generations. Q-linea develops and delivers preferred solutions for healthcare providers, enabling them to accurately diagnose and treat infectious disease in the shortest possible time. The company's lead product ASTartm is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. For more information, please visit www.qlinea.com.

For further information, please contact:

Anders Lundin, CFO and IR
Telephone: +46-706-00-15-20
E-mail: [email protected] 

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/q-linea/r/change-in-the-number-of-shares-and-votes-in-q-linea-ab,c2865550

The following files are available for download:

https://mb.cision.com/Main/17731/2865550/1079325.pdf

Press release (PDF)

 


These press releases may also interest you

at 06:00
Biohaven Ltd. , a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology, today announced the pricing of its...

at 06:00
According to a Léger survey conducted for Transplant Québec, more than three in four people favour the adoption, by Québec, of specific and comprehensive legislation governing organ donation and transplantation. At a time when the National Assembly...

at 05:30
Children's Minnesota is thrilled to announce the 32nd annual Star Gala raised $2.3 million to benefit the nonprofit pediatric health system's neuroscience program. Star Gala is regarded as one of the biggest nights of the year for the Twin Cities...

at 04:04
The European Wellness Biomedical Group (EWBG), in collaboration with the European Wellness Academy (EWA), the Baden Research Lab, and Heidelberg University, has announced substantial advances in Down Syndrome research, revealing new neuroanatomical...

at 03:30
Proprietary E3 ligase platform to enable protein stabilisation "at source", thereby restoring the body's sophisticated natural disease suppression processes Platform scales the assessment of E3 ligase targets while addressing the historic challenges...

at 03:00
Todd Britten, DMD, a board-certified periodontist and dental implant specialist in...



News published on and distributed by: